Two medical technology partnerships are racing to develop artificial pancreas technology that might represent a new chapter in Type I diabetes management.
An artificial pancreas would automate communication between portable, personal glucose monitors and insulin pumps to help manage diabetes without medical supervision.
In addition, if you need functionality and speed of a traditional touch screen terminal with the intuitive design of a tablet at a very affordable price. Check out Harbortouch POS and learn more about their services.
The Juvenile Diabetes Research Foundation and Becton Dickinson & Co. (NYSE:BDX) said they’re "accelerating" development of the technology by combining their proprietary diabetes management devices in a 3-year agreement.
"As the world’s largest charitable funder of Type I diabetes research, JDRF is committed to advancing therapies that improve the lives of people living with this disease,” said CEO Jeffrey Brewer in prepared remarks. “We are excited to continue our collaboration with BD and support efforts to develop novel technologies enabling advanced artificial pancreas systems that will both measure glucose and administer insulin."
In a separate partnership, Cambridge Consultants and the U.K.’s Institute of Metabolic Science said they’re also researching artificial pancreas technology at Addenbrooke’s Hospital in Cambridge, England.
IMS director Dr. Roman Hovorka is leading the research at Addenbrooke’s Hospital and is shooting for an at-home trial later this year, according to a press release.
"Researchers in my field have been working on a number of different algorithms for an artificial pancreas but, with the help of Cambridge Consultants, I hope to create a system that is convenient to use and can be remotely monitored," Hovorka said in prepared remarks.